2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Sara Hurvitz, MD, medical oncologist, General Internal Medicine, Hematology and Oncology at UCLA, discusses steps needed to take in the field of HER2-positive breast cancer from a research perspective.
Sara Hurvitz, MD, medical oncologist, General Internal Medicine, Hematology and Oncology at UCLA, discusses necessary steps that need to be taken in the field of HER2-positive breast cancer from a research perspective.
Researchers are beginning to have a deeper understanding of the different long-term and surgical outcomes of patients with hormone-receptor—positive, HER2-positive breast cancer compared with those who are HR-negative, Hurvitz explains. Outcomes related to PI3K activation status, she adds, may help inform decision-making and treatment options.
Looking at CDK4/6 inhibiton will also be an important area to study further, she adds. Future studies should explore combining CDK4/6 inhibitors with HER2-targeted agents as well as with endocrine therapy.
Related Content: